| Name | Title | Contact Details |
|---|
Steadfast Data Systems is a Evanston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The patient adherence software platform for pharmaceutical brands. Use gamification, behavioral economics & loyalty marketing to drive patient adherence.
Since 1970, the El Rio Community Health Center has been working to provide quality, accessible health care. Today, more than 76,000 people in the Tucson community rely on the non-profit health center as their primary source of medical and dental care. The El Rio staffs serve over 900 people per day, 76% of those served live at or below the federal poverty level. Dedicated to serving all populations including the underrepresented and uninsured, El Rio has become one of the largest non-profit, community health centers in the United States. Today, over 70,000 people access El Rio for medical and dental care. We offer quality care and help for low-income patients by using our innovative, web-based eligibility screening system, Health-e-AZ. Year after year, we work to exceed industry standards for key quality measures for preventive and chronic care. We serve the greater Tucson area and southern Arizona, improving access to care for many special population groups, including: women at risk, children, the homeless, and individuals with HIV/AIDS.
Poudre Valley Health System is a Fort Collins, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China. Our mission is to become an integrated biopharmaceutical company with significant market share in China, while establishing partnerships for global development and commercialization. Part of our strategy is to leverage our expertise and resources in North America and China to bring safer, more effective, and/or easier-to-use drugs to patients and to develop them more cost-effectively and faster using our unique dual development approach.